26,263 Shares in DexCom, Inc. (NASDAQ:DXCM) Bought by First American Bank

First American Bank acquired a new stake in shares of DexCom, Inc. (NASDAQ:DXCM) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 26,263 shares of the medical device company’s stock, valued at approximately $2,042,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Versant Capital Management Inc acquired a new position in shares of DexCom during the 4th quarter worth about $25,000. Heck Capital Advisors LLC purchased a new position in shares of DexCom in the fourth quarter valued at approximately $38,000. Midwest Capital Advisors LLC acquired a new stake in shares of DexCom in the fourth quarter worth approximately $54,000. RPg Family Wealth Advisory LLC acquired a new stake in shares of DexCom in the third quarter worth approximately $57,000. Finally, Rothschild Investment LLC increased its position in shares of DexCom by 250.5% during the fourth quarter. Rothschild Investment LLC now owns 750 shares of the medical device company’s stock worth $58,000 after purchasing an additional 536 shares in the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

DexCom Trading Down 2.3 %

Shares of NASDAQ:DXCM opened at $87.81 on Friday. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company’s 50 day moving average is $84.53 and its two-hundred day moving average is $76.55. The company has a market cap of $34.31 billion, a PE ratio of 61.41, a P/E/G ratio of 2.30 and a beta of 1.14. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. Equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current fiscal year.

Insider Transactions at DexCom

In related news, EVP Jereme M. Sylvain sold 2,090 shares of DexCom stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now directly owns 83,526 shares in the company, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the transaction, the chief operating officer now directly owns 268,644 shares in the company, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on DXCM shares. Morgan Stanley lifted their target price on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research note on Friday, February 14th. Wells Fargo & Company upped their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a report on Wednesday, December 11th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Canaccord Genuity Group increased their price target on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research note on Friday, February 14th. Finally, Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.06.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.